CytoSorbents Corporation (CTSO)

[techxen]

Advantage of extracorporeal adsorption over other therapeutic approaches

Published today in Critical Care, doctors from University of Freiburg make the argument for extracorporeal cytokine adsorption over the other therapeutic approaches. Freiburg is where the post-cardiac arrest syndrome (CYTER) and COVID-19 (CYCOV-II) trials are being run.

"A major advantage of extracorporeal cytokine adsorption over the other therapeutic approaches discussed in this debate is that it does not selectively block a specific receptor or signal transduction cascade, but it rather reduces particularly elevated concentrations of various inflammatory mediators such as interleukins, TNF-a, and also interferons; these factors have both pro- and anti-inflammatory functions. Only mildly elevated, physiological, or even decreased concentrations are not relevantly altered; thus, over-suppression of the immune response may be prevented ...."

Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03238-1